公开(公告)号：US12227520B2

公开(公告)日：2025-02-18

申请号：US18050650

申请日：2022-10-28

Applicant: Gilead Sciences, Inc.

Inventor： Hang Chu ,  Ana Z. Gonzalez Buenrostro ,  Hongyan Guo ,  Xiaochun Han ,  Lan Jiang ,  Jiayao Li ,  Michael L. Mitchell ,  Hyung-Jung Pyun ,  Scott D. Schroeder ,  Gregg M. Schwarzwalder ,  Nathan D. Shapiro ,  Devleena M. Shivakumar ,  Qiaoyin Wu ,  Hong Yang ,  Jennifer R. Zhang

IPC: C07D498/18 ,  A61P31/18 ,  C07D471/18

Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US12180197B2

公开(公告)日：2024-12-31

申请号：US17690851

申请日：2022-03-09

Applicant: Gilead Sciences, Inc.

Inventor： Gediminas J. Brizgys ,  Chienhung Chou ,  Jeromy J. Cottell ,  Chao-I Hung ,  Michael L. Mitchell ,  Scott D. Schroeder ,  Nathan D. Shapiro ,  Suzanne M. Szewczyk ,  James G. Taylor ,  Nathan E. Wright ,  Sheila M. Zipfel

IPC: C07D405/14 ,  A61K31/4545 ,  A61K31/4725 ,  A61K45/06 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

公开(公告)号：US11858918B2

公开(公告)日：2024-01-02

申请号：US17724212

申请日：2022-04-19

Applicant: Gilead Sciences, Inc.

Inventor： Megan K. Armstrong ,  James S. Cassidy ,  Elbert Chin ,  Chienhung Chou ,  Jeromy J. Cottell ,  Chao-I Hung ,  Kavoos Kolahdouzan ,  David W. Lin ,  Michael L. Mitchell ,  Ezra Roberts ,  Scott D. Schroeder ,  Nathan D. Shapiro ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang

IPC: C07D405/14 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  C07D401/08 ,  C07D401/10 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D493/08 ,  C07D493/10 ,  C07F9/6558

CPC classification number: C07D405/14 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  C07D401/08 ,  C07D401/10 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D493/08 ,  C07D493/10 ,  C07F9/65586

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

公开(公告)号：US20230027019A1

公开(公告)日：2023-01-26

申请号：US17361758

申请日：2021-06-29

Applicant: Gilead Sciences, Inc.

Inventor： Hang Chu ,  Ana Z. Gonzalez Buenrostro ,  Hongyan Guo ,  Xiaochun Han ,  Lan Jiang ,  Jiayao Li ,  Michael L. Mitchell ,  Hyung-Jung Pyun ,  Scott D. Schroeder ,  Gregg M. Schwarzwalder ,  Nathan D. Shapiro ,  Devleena M. Shivakumar ,  Qiaoyin Wu ,  Hong Yang ,  Jennifer R. Zhang

IPC: C07D498/18 ,  C07D471/18 ,  A61P31/18

Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US11548902B1

公开(公告)日：2023-01-10

申请号：US17361758

申请日：2021-06-29

Applicant: Gilead Sciences, Inc.

Inventor： Hang Chu ,  Ana Z. Gonzalez Buenrostro ,  Hongyan Guo ,  Xiaochun Han ,  Lan Jiang ,  Jiayao Li ,  Michael L. Mitchell ,  Hyung-Jung Pyun ,  Scott D. Schroeder ,  Gregg M. Schwarzwälder ,  Nathan D. Shapiro ,  Devleena M. Shivakumar ,  Qiaoyin Wu ,  Hong Yang ,  Jennifer R. Zhang

IPC: C07D498/18 ,  C07D471/18 ,  A61P31/18

Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US11084832B2

公开(公告)日：2021-08-10

申请号：US16825142

申请日：2020-03-20

Applicant: Gilead Sciences, Inc.

Inventor： Hang Chu ,  Ana Z. Gonzalez Buenrostro ,  Hongyan Guo ,  Xiaochun Han ,  Lan Jiang ,  Jiayao Li ,  Michael L. Mitchell ,  Hyung-Jung Pyun ,  Scott D. Schroeder ,  Gregg M. Schwarzwalder ,  Nathan D. Shapiro ,  Devleena M. Shivakumar ,  Qiaoyin Wu ,  Hong Yang ,  Jennifer R. Zhang

IPC: C07D498/18 ,  C07D471/18 ,  A61P31/18

Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US12161625B2

公开(公告)日：2024-12-10

申请号：US18059806

申请日：2022-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192 ,  A61P31/20 ,  C07D487/04 ,  C07D519/00

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20240254118A1

公开(公告)日：2024-08-01

申请号：US18391258

申请日：2023-12-20

Applicant: Gilead Sciences, Inc.

Inventor： Megan K. Armstrong ,  Elbert Chin ,  Chienhung Chou ,  Laurent P. Debien ,  Joshua D. Farr ,  Pancham Lal Gupta ,  Chao-I Hung ,  Michael L. Mitchell ,  Prasenjit K. Mukherjee ,  Shaina V. Nguyen ,  Gregory T. Notte ,  Daniel Roa ,  Adam J. Schrier ,  Zheng-Yu Yang

IPC: C07D471/04 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/4745 ,  A61K31/4748 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  C07D401/12 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/4745 ,  A61K31/4748 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  C07D401/12 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00

Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.

公开(公告)号：US11878965B2

公开(公告)日：2024-01-23

申请号：US17557860

申请日：2021-12-21

Applicant: Gilead Sciences, Inc.

Inventor： Daniel H. Byun ,  Zhenhong R. Cai ,  Eda Y. Canales ,  Laurent P. Debien ,  Timothy R. Hansen ,  Richard Huang ,  Petr Jansa ,  Rick A. Lee ,  Jennifer A. Loyer-Drew ,  Ryan McFadden ,  Michael L. Mitchell ,  Hyung-Jung Pyun ,  Roland D. Saito ,  Michael S. Sangi ,  Adam J. Schrier ,  Marina E. Shatskikh ,  James G. Taylor ,  Joshua J. Van Veldhuizen ,  Lianhong Xu

IPC: C07D401/04 ,  A61K31/437 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5383 ,  A61K45/06 ,  C07D401/14 ,  C07D519/00

CPC classification number: C07D401/04 ,  A61K31/437 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5383 ,  A61K45/06 ,  C07D401/14 ,  C07D519/00

Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

公开(公告)号：US20230257389A1

公开(公告)日：2023-08-17

申请号：US18164317

申请日：2023-02-03

Applicant: Gilead Sciences, Inc.

Inventor： Hang Chu ,  Ana Z. Gonzalez Buenrostro ,  Hongyan Guo ,  Xiaochun Han ,  Anna E. Hurtley ,  Lan Jiang ,  Jiayao Li ,  David W. Lin ,  Michael L. Mitchell ,  Devan Naduthambi ,  Gregg M. Schwarzwalder ,  Suzanne M. Szewczyk ,  Matthew J. Von Bargen ,  Qiaoyin Wu ,  Hong Yang ,  Jennifer R. Zhang

IPC: C07D487/18 ,  A61P31/18 ,  C07D487/22 ,  C07D491/22

CPC classification number: C07D487/18 ,  A61P31/18 ,  C07D487/22 ,  C07D491/22

Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.